New progress in research and application of foldable artificial vitreous balloon

doi:10.3877/cma.j.issn.2095-2007.2021.02.008

Abstract

Abstract:

Foldable capsular vitreous body (FCVB) is an innovative vitreous substitute developed independently by China. It is a global innovative product, which is composed of a computer simulated capsule, a drainage tube and a drainage valve. FCVB′s material was made by modified liquid silicone rubber which has good physical properties and biocompatibility. FCVB could be filled with silicone oil, or balanced salt solution after folding intraocular implantation, providing a 360-degree fulfilled support. It is mainly used in patients with severe retinal detachment who can not be treated with existing vitreous substitutes. Additionally, some studies have confirmed that FCVB also could be used as a drug delivery device to release a variety of drugs, namely a novel combination of vitreous substitute and drug delivery system. FCVB has good application prospects, but there are still some problems, which need to be further studied and improved on such as the number of clinical applications being small, and investigate the effects of long-term application.

Key words: Foldable capsular vitreous body, Vitreous substitute, Retinal detachment, Silicone oil, Vitrectomy

Baihui Zeng, Qian Wang, Ning Han, Guiqin Sui. New progress in research and application of foldable artificial vitreous balloon[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2021, 11(02): 104-108.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2021.02.008

https://zhykyxzz.cma-cmc.com.cn/EN/Y2021/V11/I02/104

References 51

[1]	Gao Q, Mou S, Ge J, et al. A new strategy to replace the natural vitreous by a novel capsular artificial vitreous body with pressure-control valve[J]. Eye (Lond), 2008, 22(3): 461-468.
[2]	Liu Y, Jiang Z, Gao Q, et al. Technical standards of a foldable capsular vitreous body in terms of mechanical, optical, and biocompatible properties[J]. Artif Organs, 2010, 34(10): 836-845.
[3]	Chen J, Gao Q, Liu Y, et al. Clinical device-related article evaluation of morphology and functions of a foldable capsular vitreous body in the rabbit eye[J]. J Biomed Mater Res B Appl Biomater, 2011, 97(2): 396-404.
[4]	Chen H, Feng S, Liu Y, et al. Functional evaluation of a novel vitreous substitute using polyethylene glycol sols injected into a foldable capsular vitreous body[J]. J Biomed Mater Res A, 2013, 101(9): 2538-2547.
[5]	Mariacher S, Szurman P. Artificial vitreous body: Strategies for vitreous body substitutes[J]. Ophthalmologe, 2015, 112(7): 572-579.
[6]	Donati S, Caprani Sm, Airaghi G, et al. Vitreous substitutes: the present and the future[J]. Biomed Res Int, 2014: 351804.
[7]	Januschowski K, Seuthe AM, Boden KT, et al. Novel vitreous body replacement with hydrogel？[J]. Ophthalmologe, 2018, 115(8): 692-696.
[8]	Deuchler S, Ackermann H, Singh P, et al. Key Factors to Improve the Outcome of Retinal Reattachment Surgery in Proliferative Vitreoretinopathy and Proliferative Diabetic Retinopathy[J]. J Ophthalmol, 2017: 2323897.
[9]	Durand Ml. Bacterial and Fungal Endophthalmitis[J]. Clin Microbiol Rev, 2017, 30(3): 597-613.
[10]	Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update[J]. Retina, 2015, 35(2): 165-175.
[11]	Rejdak R, Juenemann AG, Natarajan S. Posterior Segment Ocular Trauma: Timing and Indications for Vitrectomy[J]. J Ophthalmol, 2017: 5250924.
[12]	Soman N, Banerjee R. Artificial vitreous replacements[J]. Biomed Mater Eng, 2003, 13(1): 59-74.
[13]	Chen Y, Kearns VR, Zhou L, et al. Silicone oil in vitreoretinal surgery: indications, complications, new developments and alternative long-term tamponade agents[J]. Acta Ophthalmol, 2020: 14604.
[14]	Pichi F, Hay S, Abboud EB. Inner retinal toxicity due to silicone oil: a case series and review of the literature[J]. Int Ophthalmol, 2020, 40(9): 2413-2422.
[15]	Branisteanu DC, Moraru AD, Maranduca MA, et al. Intraocular pressure changes during and after silicone oil endotamponade (Review)[J]. Exp Ther Med, 2020, 20(6): 204.
[16]	Nicolai M, Lassandro N, Franceschi A, et al. Intraocular Pressure Rise Linked to Silicone Oil in Retinal Surgery: A Review[J]. Vision (Basel), 2020, 4(3): 36.
[17]	Barca F, Caporossi T, Rizzo S. Silicone Oil: Different Physical Proprieties and Clinical Applications[J]. Journal of Biomedicine and Biotechnology, 2014: 502143.
[18]	Liu Z, Fu G, Liu A. The relationship between inflammatory mediator expression in the aqueous humor and secondary glaucoma incidence after silicone oil tamponade[J]. Exp Ther Med, 2017, 14(6): 5833-5836.
[19]	La CM, Lux A, Heegaard S. Visual loss under silicone oil[J]. Klin Monbl Augenheilkd, 2010, 227(3): 181-184.
[20]	Su X, Tan MJ, Li Z, et al. Recent Progress in Using Biomaterials as Vitreous Substitutes[J]. Biomacromolecules, 2015, 16(10): 3093-3102.
[21]	Steijns D, Stilma JS. Vitrectomy: in search of the ideal vitreous replacement[J]. Ned Tijdschr Geneeskd, 2009, 153(35): 433.
[22]	Cheng NX, Wang Yl, Wang JH, et al. Complications of breast augmentation with injected hydrophilic polyacrylamide gel[J]. Aesthetic Plast Surg, 2002, 26(5): 375-382.
[23]	Qiao Q, Wang X, Sun J, et al. Management for postoperative complications of breast augmentation by injected polyacrylamide hydrogel[J]. Aesthetic Plast Surg, 2005, 29(3): 156-161.
[24]	Benediktsson K, Perbeck L. Capsular contracture around saline-filled and textured subcutaneously-placed implants in irradiated and non-irradiated breast cancer patients: five years of monitoring of a prospective trial[J]. J Plast Reconstr Aesthet Surg, 2006, 59(1): 27-34.
[25]	Bingham HG, Copeland EM, Hackett R, et al. Breast cancer in a patient with silicone breast implants after 13 years[J]. Ann Plast Surg, 1988, 20(3): 236-237.
[26]	Glatt BS, Afifi G, Noone RB. Long-term follow-up of a sponge breast implant and review of the literature[J]. Ann Plast Surg, 1999, 42(2): 196-201.
[27]	Mirza RG, Johnson MW, Jampol LM. Optical Coherence Tomography Use in Evaluation of the Vitreoretinal Interface: A Review[J]. Survey of Ophthalmology, 2007, 52(4): 397-421.
[28]	Lin X, Ge J, Gao Q, et al. Evaluation of the flexibility, efficacy, and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment[J]. Invest Ophthalmol Vis Sci, 2011, 52(1): 374-381.
[29]	Lin X, Wang Z, Jiang Z, et al. Preliminary efficacy and safety of a silicone oil-filled foldable capsular vitreous body in the treatment of severe retinal detachment[J]. Retina, 2012, 32(4): 729-741.
[30]	Schwartz SG, Flynn HW, Mieler WF. Update on retinal detachment surgery[J]. Current Opinion in Ophthalmology, 2013, 24(3): 255-261.
[31]	高前应. 折叠式人工玻璃体临床试用和生产[J]. 中国科技成果，2013，21: 32-32.
[32]	Wang P, Gao Q, Jiang Z, et al. Biocompatibility and retinal support of a foldable capsular vitreous body injected with saline or silicone oil implanted in rabbit eyes[J]. Clin Exp Ophthalmol, 2012, 40(1): e67-e75.
[33]	Liu Y, Ke Q, Chen J, et al. Sustained mechanical release of dexamethasone sodium phosphate from a foldable capsular vitreous body[J]. Invest Ophthalmol Vis Sci, 2010, 51(3): 1636-1642.
[34]	Jiang Z, Wang P, Pan B, et al. Evaluation of levofloxacin release characteristics from a human foldable capsular vitreous body in vitro[J]. J Ocul Pharmacol Ther, 2012, 28(1): 33-40.
[35]	Wang T, Huang X, Gao Q, et al. A preliminary study to treat severe endophthalmitis via a foldable capsular vitreous body with sustained levofloxacin release in rabbits[J]. Invest Ophthalmol Vis Sci, 2013, 54(1): 804-812.
[36]	Chen X, Liu Y, Jiang Z, et al. Protein kinase Calpha downregulation via siRNA-PKCalpha released from foldable capsular vitreous body in cultured human retinal pigment epithelium cells[J]. Int J Nanomedicine, 2011, 6: 1303-1311.
[37]	Zheng H, Wang Z, Wang P, et al. Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo[J]. Graefes Arch Clin Exp Ophthalmol, 2012, 250(5): 751-759.
[38]	Zhang R, Wang T, Xie C, et al. Evaluation of supporting role of a foldable capsular vitreous body with magnetic resonance imaging in the treatment of severe retinal detachment in human eyes[J]. Eye (Lond), 2011, 25(6): 794-802.
[39]	Wang P, Gao Q, Lin X, et al. Comprehensive analysis of inflammatory immune mediators of the intraocular fluid aspirated from the foldable capsular vitreous body filled-eyes[J]. PLoS One, 2012, 7(10): e46384.
[40]	Zhang X, Tian X, Zhang B, et al. Study on the effectiveness and safety of Foldable Capsular Vitreous Body implantation[J]. BMC Ophthalmol, 2019, 19(1): 260.
[41]	Yang W, Yuan Y, Zong Y, et al. Preliminary study on retinal vascular and oxygen-related changes after long-term silicone oil and foldable capsular vitreous body tamponade[J]. Sci Rep, 2014, 4: 25272.
[42]	Lin X, Sun X, Wang Z, et al. Three-Year Efficacy and Safety of a Silicone Oil-Filled Foldable-Capsular-Vitreous-Body in Three Cases of Severe Retinal Detachment[J]. Transl Vis Sci Technol, 2016, 5(1): 2.
[43]	Gao QY, Fu Y, Hui YN. Vitreous substitutes: challenges and directions[J]. Int J Ophthalmol, 2015, 8(3): 437-440.
[44]	Feng S, Chen H, Liu Y, et al. A novel vitreous substitute of using a foldable capsular vitreous body injected with polyvinylalcohol hydrogel[J]. Sci Rep, 2013, 3: 1838.
[45]	张贵森，巩慧，惠延年，等. 折叠式人工玻璃体球囊植入的初步临床实践[J]. 国际眼科杂志，2018，18(3): 578-580.
[46]	郝琳娜，毕春潮，王睿. 折叠式人工玻璃体球囊的临床应用[J]. 临床眼科杂志，2019，27(4): 331-333.
[47]	李晓丹，张百珂，贾雍，等. 折叠式人工玻璃体球囊植入在玻璃体视网膜疾病治疗中的应用[J]. 眼科新进展，2020，40(7): 670-673.
[48]	苏鹏，孔祥斌，黄玉娟，等. 折叠式人工玻璃体球囊在外伤性硅油依赖眼中的临床应用[J]. 实用临床医学，2020，21(7): 52-54.
[49]	Zhang B, Li C, Jia Y, et al. A pilot clinical study of treating rhegmatogenous retinal detachment by silicone rubber balloon scleral buckling[J]. Retina, 2020, 40(10): 1918-1928.
[50]	Haller J, Bandello F, Belfort R, et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion[J]. Ophthalmology, 2010, 117(6): 1134-1146.
[51]	Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an Intravitreal Fluocinolone Acetonide Implant versus Standard Systemic Therapy in Noninfectious Posterior Uveitis[J]. Ophthalmology, 2010, 117(3): 567-575.

Please choose a citation manager

Content to export